Experts' Perspectives: Advancements in Cardiomyopathy at ACC.24

In recent years, advancements in the treatment of cardiomyopathies have captivated the cardiology community. However, experts and opinion leaders in cardiomyopathy are quick to remind others this progress was not overnight and comes as the result of tireless efforts by colleagues and their predecessors dating back decades.
In the last decade, a greater understanding of pathophysiology has given way to numerous advances in management, including the introduction of cardiac myosin inhibitors into treatment algorithms of patients with obstructive hypertrophic cardiomyopathy, such as mavacamten (Camzyos), which received approval for obstructive hypertrophic cardiomyopathy in April 2022. Now, the community looks ahead with anticipation to phase 3 data for a next-generation cardiac myosin inhibitor in aficamten.
At the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions, investigators presented data from the 1-year cohort of FOREST-HCM, which is an ongoing open-label extension study. In the presentation, investigators detailed the results of the first 45 patients to achieve 1-year of follow-up.
If this were not enough, the field was given hope for a potential treatment for the management of nonobstructive hypertrophic cardiomyopathy with the results of the IMPROVE-HCM trial, which examined use of the cardiac mitotrope ninerafaxstat. Presented at ACC.24, results of the trial indicate use of ninerafaxstat was associated with a non-significant LS mean difference of 3.1 between the groups (P=.2) for change in KCCQ-CSS from baseline to the end of the treatment period, with a greater proportion of patients receiving ninerafaxstat achieving an improvement in KCCQ-CSS of 5 or more, 10 or more, or 20 or more points.
For more perspective on the advancement events in cardiomyopathy, check out our interview with key opinion leaders Sara Saberi, MD, Martin Maron, MD, and Ahmad Masri, MD.
www.hcplive.com/view/expert-s...